Background. A 48-year-old man presented with diarrhea, flushing, abdominal pain and weight loss of 10 kg over a 6-month period. He subsequently developed dyspnea on exertion. Diagnosis. Carcinoid ...

COX, cyclo-oxygenase; IHS, immunohistochemical score; NS, not statistically significant; NSE, neuron-specific enolase ...

finger-like pouch attached to the big intestine, is home to distinct forms of cancer. Mucinous adenocarcinomas, signet ring cell adenocarcinomas, and neuroendocrine tumours (carcinoid tumours ...

Exelixis, Inc. (Nasdaq: EXEL) today announced that the U.S. Food and Drug Administration (FDA) has approved CABOMETYX® (cabozantinib) for the treatment of 1) adult and pediatric patients 12 years of ...

Identical to MIB1. ‡ Gastrointestinal neuroendocrine tumor. § Pancreatic neuroendocrine tumor. NET: Neuroendocrine tumor. Data from [20,94]. T1 Tumor limited to the pancreas and size <2 cm T2 ...

Based on the phase 3 CABINET trial, the FDA approved Cabometyx for some patients with previously treated neuroendocrine ...

The findings of the study support an antiproliferative effect in well-differentiated, midgut carcinoid tumors ... treatment of metastatic intestinal neuroendocrine tumors.

Jennifer Chan, MD, MPH, discussed outcomes of treating neuroendocrine tumors (NETs) with cabozantinib depending on whether they were pancreatic NETs or extrapancreatic NETs.

The study was led by Jennifer Chan, MD, MPH, clinical director of the gastrointestinal cancer center and director of the program in carcinoid and neuroendocrine tumors at Dana-Farber Cancer Institute.

Carcinoid tumors: also monitor urinary 5-HIAA, plasma serotonin, plasma Substance P. VIPomas: also monitor plasma vasoactive intestinal peptide. Discontinue and treat if cholelithiasis ...

– FDA approval based on the phase 3 CABINET pivotal trial, which demonstrated a statistically significant and clinically meaningful improvement in progression-free survival versus placebo ...